Newsroom-Katalog
| Zeit | Boehringer Ingelheim: Meldungen vom 03.08.2009 |
|---|---|
| 07:08 | Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations |